As a result, some scientists have investigated the usefulness of selective COX-2 inhibitors, such as SC-236 and Celecoxib, in vitro and in vivo to test whether their inhibition can sensitize tumor cells to make treatment more efficient against cancer using chemotherapy and radiotherapy. Here, PTGS2 is linked to cancer.